Endogenex plans to use the funds to complete a pivotal trial of its endoscopic type 2 diabetes treatment and support a ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

Introduction Diabetes distress is a common health problem among people living with type 2 diabetes (T2D), making it difficult to manage the condition. Though it remains a problem, limited attention ...

Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...

Future guidelines may integrate emerging evidence and novel therapeutic strategies for CKD, T2D, and CVD management. Personalized treatment plans considering the interplay between CKD, T2D, and CVD ...

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like ...

CHICAGO – “Lean type 2 diabetes (T2D)” is a diagnosis of exclusion but is also a true entity affecting roughly 10%-20% of people with T2D. That was the message from Kristina Utzschneider, MD, ...

Pharmaceutical companies are developing new weight-loss treatments that aim to shed the pounds while preserving muscle mass -- a downside of current drugs. (Reuters via MSN) In a phase Ib trial, ...

This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice. Conclusions: ...

The majority of patients with type 2 diabetes (T2D) have less than ideal metabolic control despite our greater understanding of the underlying pathophysiologic mechanisms of hyperglycemia and the ...

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials Leveraging whole-genome sequencing data from the St Jude Lifetime ...